x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012246
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB, IHC, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro364 of human malic enzyme 2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ME2 |
| UniProt No. | P23368 |
| Gene ID | 4200 |
| Gene Description | Malic enzymes catalyze oxidative decarboxylation of malate to pyruvate. The malic enzyme family in mammalian cells includes the cytosolic malic enzyme 1 and two mitochondrial malic enzymes. ME1 and ME2 are critical for tumor cell growth and their expression is repressed by tumor suppressor p53. Reduced expression of ME1 and ME2 reciprocally increases the levels and activation of p53, promoting p53-mediated senescence. Research studies show ME3 is essential for the survival of pancreatic ductal adenocarcinoma following genomic deletion of ME2. Deletion of ME3 is lethal to ME2-null cancer cells, which has been suggested to provide a potential therapeutic opportunity using collateral lethality. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
